Moderna has been ordered to pay almost £44,000 after 12-year-olds were encouraged to join Covid vaccine trials with the ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Moderna has been awarded approximately ... expands the clinical data supporting the use of mRNA vaccines that may be needed if other influenza strains emerge with pandemic potential." MORE: What 3rd ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV ... candidate can successfully crea Reports third quarter revenues of $1.9 billion, GAAP net income ...